VEEVA-SYSTEMS-INC.
14.10.2020 13:05:11 CEST | Business Wire | Press release
Veeva Systems (NYSE: VEEV) today announced that Exact Sciences, a leading provider of cancer screening and diagnostic tests, selected Veeva Vault Clinical Suite to design and run its clinical studies. Exact Sciences will use Veeva Vault CDMS , Veeva Vault CTMS , and Veeva Vault eTMF to streamline clinical data and trial processes on a single cloud platform. With a unified suite of applications, Exact Sciences can stay ahead of ever-changing regulations such as EU IVDR and MDR.
“We are modernizing our trial processes with Veeva to get the next generation of cancer tests to patients quickly,” said Sandra Statz, senior vice president of clinical and regulatory affairs at Exact Sciences. “Veeva Vault Clinical Suite allows us to streamline our clinical studies from build to close and accelerate the development of potential life-changing products.”
Exact Sciences is at the forefront of advanced diagnostics for early cancer detection, treatment guidance, and monitoring. With Vault Clinical Suite, Exact Sciences can scale to run more trials, speed innovations, ensure compliance, and increase overall efficiency.
The Vault Clinical Suite modernizes end-to-end study processes with unified applications for clinical data management and clinical operations. Vault CDMS shortens database build times for studies of all types. Interactive reports in Vault CTMS provide real-time visibility to proactively track milestones and manage studies. Vault eTMF enables real-time management of TMF processes and documents as they are being executed to stay inspection ready.
“As a fast-growing diagnostics company, Exact Sciences needed a partner to keep up with their pace of innovation,” said Jim Diefenbach, general manager of Veeva Medical Device and Diagnostics. “Veeva is helping Exact Sciences efficiently manage clinical processes and data, advance product development, and remain agile throughout their clinical studies.”
Veeva Vault provides unified suites of cloud applications for medical device and diagnostics companies to manage regulated content and data throughout the product lifecycle, including the Vault Clinical , Vault Quality , Vault Regulatory , Vault Medical , and Vault Commercial Content Management suites.
Learn more at the upcoming Veeva Medical Device & Diagnostics Summit , October 28-29, 2020. The online event is open to life sciences industry professionals. Learn more and register at veeva.com/MedDeviceSummit .
Additional Information
For more on Veeva Medical Device & Diagnostics, visit: veeva.com/MedDevice
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005114/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Speech Processing Solutions Launches Philips SpeechLive Health, an AI Assistant Built for Modern Clinical Documentation17.3.2026 15:00:00 CET | Press release
Philips SpeechLive Health AI Assistant uses healthcare-trained AI to convert clinical conversations into structured notes, helping clinicians reduce administrative burden Speech Processing Solutions, the global leader in professional dictation and speech solutions sold under the Philips brand, today announced the upcoming April 2026 launch of Philips SpeechLive Health AI Assistant, an AI-powered clinical documentation assistant designed for healthcare professionals across multiple care settings. This solution reduces administrative burden, streamlines documentation, and improves provider and patient experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317743584/en/ Philips SpeechLive Health AI Assistant turns clinical conversations into structured documentation, helping reduce administrative workload and create more time for patient care. Purpose-built for clinical documentation workflows Clinical workload remains
Moody’s Ratings Becomes First Credit Rating Agency to Bring Independent Credit Analysis to Blockchain Financial Infrastructure17.3.2026 15:00:00 CET | Press release
Moody’s Corporation (NYSE: MCO) today announced that Moody’s Ratings has launched its network-agnostic Token Integration Engine™ (TIE), becoming the first credit rating agency to ingest analytical data and share credit insights on-chain. As an inaugural step, it is the first rating agency to operate a node on the Canton Network. The milestone marks a significant step in Moody’s commitment to digital innovation, intending to enable secure, compliant, and efficient ingestion of data and dissemination of ratings enabled by technology built for integration across platforms. “As financial markets digitize, the need for independent, trusted risk analysis and credit insights does not change,” said Fabian Astic, Managing Director and Global Head of Digital Economy at Moody’s Ratings. “Moody’s Ratings is extending that rigor to digital market infrastructure consistent with global regulatory expectations and our governance, transparency, and compliance practices.” Moody’s Ratings’ TIE serves as
Coherent Solutions Releases Research on AI-driven Fraud Prevention in Banking and Finance and the Best AI Models for Banks17.3.2026 15:00:00 CET | Press release
Coherent Solutions has released a Future of Finance research illustrating how AI is advancing fraud detection in financial services. The research offers financial institutions a strategic framework to address rising and more sophisticated fraud techniques with adaptive, human-in-the-loop AI systems, based on the firm’s extensive experience in AI engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317526196/en/ Coherent Solutions releases research on AI-driven fraud prevention. This white paper addresses the modern threat of transaction fraud, which is becoming faster and smarter while conventional rule-based systems lag, leaving financial institutions exposed. Banks, credit lenders, and financial institutions that adopt AI and machine learning can reduce fraud losses by up to 50% and detect anomalies in real time. When implemented with proper governance and human oversight, AI systems also make audits smoother and
The Swoosh Meets the ‘b’: Beats and Nike Unveil Historic First-Ever Collaboration for Powerbeats Pro 217.3.2026 15:00:00 CET | Press release
LeBron James trades the court for the course in a star-studded campaign celebrating the ultimate performance crossover Today, Beats and Nike announced the first hardware collaboration in their shared history: Powerbeats Pro 2 – Nike Special Edition. In a landmark design shift, Beats has—for the first time—shared its iconic earbud real estate with a partner, featuring the Nike Swoosh on the right bud and the signature Beats “b” on the left. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317159868/en/ Powerbeats Pro 2 - Nike Special Edition The limited-edition release marries Nike’s high-energy “Volt” color palette with the industry-leading audio tech of the Powerbeats Pro 2. The result is a performance tool built to bridge the gap between elite sport and street style. The Nike Special Edition arrives in a striking matte black, Volt-speckled charging case. Upon opening, users are greeted by Nike’s “JUST DO IT” mantra printe
Sub-Q Bionics Announces Licensing Agreement to Advance Lymphedema Care17.3.2026 14:46:00 CET | Press release
Sub‑Q Bionics, a medical device company developing an innovative implantable lymphatic drainage system designed to help patients living with lymphedema better manage their symptoms, today announced a licensing agreement with Mayo Clinic. Through the agreement, Sub-Q Bionics has licensed clinical know-how from Mayo Clinic related to reconstructive and lymphatic surgery. As part of this collaboration, Vahe Fahradyan, M.D., a plastic and reconstructive surgeon with expertise in lymphatic surgery, plans to work with Sub-Q Bionics as a clinical collaborator supporting the company’s ongoing development activities. Lymphedema is a chronic condition caused by impaired lymphatic drainage that can lead to persistent swelling, discomfort, and reduced mobility. It commonly occurs following cancer treatment, particularly among breast cancer survivors. Sub-Q Bionics is developing the world’s first implantable bionic lymphatic drainage system designed to assist with movement of lymphatic fluid and he
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom